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A report on the IBC USA International Microtechnology
Conference ‘Chips to hits’, San Diego, USA, 27 October to
1 November 2001.
The  ‘Chips  to  hits’  meeting  gathered  approximately  1,200
scientists and covered recent advances in the fields of gene
expression, protein arrays and molecular diagnostics. There
were  also  three  pre-conference  sessions  on  surface  chem-
istry, bioinformatics and nano-biotechnology. 
Surface chemistry
In order to develop protein arrays, specialized coatings are
needed  for  slides;  there  is  currently  rapid  growth  in  the
coating  chemistry  field.  Several  investigators,  including
Malcolm Pluskal (Proteome Systems, Acton, USA) and Karin
Hughes (ProlinX, Bothell, USA) talked about their ongoing
coating chemistry projects. Pluskal gave an overview of the
basic properties of surfaces and how they have been modi-
fied  to  immobilize  cDNAs,  oligonucleotides,  proteins  and
antibodies.  He  described  the  coatings  used  on  metal  sur-
faces,  especially  on  noble  metals  such  as  gold,  including
long-chain  alkyl  thioester  monomers  and  self-assembling
monolayers. Glass surfaces can be treated with thin layers of
silane  reagents  (aminopropyl-,  mercaptopropyl-,  methyl-
propyl-, and epoxy-silane), avidin and streptavidin, poly-L-
lysine,  glutaraldehyde,  or  polyacrylamide.  These  coating
chemistries have been applied in the development of DNA
chips,  protein  arrays  and  surface  plasmon  resonance
sensors. Pluskal also discussed piezoelectric liquid dispens-
ing technology, which has applications in peptide-mass fin-
gerprinting,  mapping  sites  of  N-glycosylation,  antigen
discovery and immunodiagnostics. ‘Chemical printing’ by in
situ tryptic digestion of membrane-bound proteins directly
on the blot was highlighted as a very useful approach for
quantitating proteins, because it needs only small amounts
of reagents that can be delivered precisely, archiving of the
results  is  possible  and,  most  importantly,  it  can  be  auto-
mated for high-throughput quantitation purposes. 
Hughes presented information on her company’s Versalinx
protein  array  technology  platform,  which  uses  glass  slides
coated  with  phenyl-(di)-boronic  acid  to  bind  reversibly  to
salicyl hydroxamic acid. This non-biological surface chemistry
has  several  advantages,  such  as  excellent  surface  stability,
good retention of proteins, the capacity to bind all different
proteins, and a uniform signal strength and spot morphology.
This type of self-assembled, monolayer surface chemistry is
highly  compatible  with  types  of  mass  spectrometry  such  as
matrix absorption laser time-of-flight (MALDI) and surface-
enhanced laser time-of-flight (SELDI) spectrometry. 
Microarrays for genomics and diagnostics
Several  speakers  described  the  applications  of  microarrays
for  genomics  and  diagnostics.  Elizabeth  Winzeler  (The
Scripps Research Institute, San Diego, USA) used a system
based on screening of individual yeast cells as a tool for drug
discovery. Using this approach, she has identified inhibitors
of specific cellular processes and targets and found that these
are  active  not  only  in  yeast  but  also  on  a  broad  range  of
pathogens. The biggest advantage of the cell-based screening
method is the ability to screen thousands of targets simulta-
neously; the assays may not be very sensitive, however. Using
Affymetrix yeast gene chips and yeast grown in rich media,
she  has  identified  new,  not-yet-annotated  open  reading
frames and further validated their expression at the mRNA
level by northern-blot analysis. Using different growth condi-
tions  and  nocodazole  treatment  (which  destabilizes  micro-
tubules)  she  has  monitored  phenotypes  and  systematically
identified  potential  new  open  reading  frames.  In  addition,
she  presented  results  on  identification  of  DNA-damage
response genes by treating yeast cells with ultra-violet light. 
Currently,  many  researchers  use  low-throughput  analyses
such  as  restriction-fragment  length  polymorphism  andsingle strand conformational polymorphism for genotyping,
but to analyze large numbers of SNPs from many samples,
array-based  and/or  mass  spectrometry  techniques  are
needed. Charles Cantor (Sequenom, San Diego, USA) pre-
sented  an  approach  to  gene  discovery  that  involves  fully
automated  genotyping  by  mass  spectrometry.  Using  this
method he has identified apolipoprotein E as a marker for
Alzheimer’s  disease,  confirming  previous  work.  He  noted
that using this method, 190,000 validated assays can be per-
formed  and  1.3  million  single  nucleotide  polymorphisms
(SNPs) can be tested per year. His group are also looking at
various disease markers and biochemical risk factors in the
general  population.  He  detailed  a  strategy  for  detecting
genes  involved  in  cardiovascular  disease  by  measuring
adenine:guanine ratios in high-density lipoprotein and low-
density lipoprotein genes in DNA pools from twins. In order
to screen for genetic markers for use in the clinic and for
population studies, they have collected and deposited DNA
samples from about 10,000 healthy patients in their propri-
etary DNA bank.
Towia Libermann (Harvard Medical School, Boston, USA)
demonstrated the power of the ‘multiplexed molecular pro-
filing technology’ platform in the identification of targets for
epithelial-specific transcription factors involved in epithelial
cell differentiation and proliferation, using prostate cancer
as a model. His group has discovered a new family of human
Ets-related transcription factors that include ESE-1, ESE-2,
ESE-3,  and  prostate  down-regulated  expressed  factor
(PDEF) and have characterized them and determined their
mRNA localization using in situ hybridization. In an attempt
to  identify  target  genes  for  the  Ets  transcription  factors,
LNCaP  prostrate  cancer  cell  lines  were  stably  transfected
with PDEF. The overexpression of PDEF was confirmed by
GeneChip analysis and validated by real-time PCR. They
analyzed the regulatory pathway after treating the cell line
with  interleukin-6,  leading  to  the  isolation  of  nuclear
factor B  as  a  potential  therapeutic  target  for  prostate
cancer.  Libermann  also  presented  data  on  genotyping  of
type 1 diabetes patients using the Nanogen microelectronic
chip  technology  platform;  his  group  has  found  SNPs  that
were associated with Ets genes.
Emerging technologies
There were several presentations on cutting-edge technolo-
gies. M. Richard Shen (Illumina, San Diego, USA) presented
data on high-throughput genotyping using arrays of oligonu-
cleotides on microspheres (beads) attached to high-density
optical  fibers.  Illumina manufactures  these  oligonu-
cleotide-coated bead arrays by a self-assembly process that
takes place in a random fashion on the end of a fiber-optic
bundle. Approximately 2,000 different oligonucleotides can
be attached to each bead, meaning that 2,000 assays can be
performed  per  array.  The  bead-bound  oligonucleotides
hybridize to complementary sequences that are generated in
genotyping  assays,  in  which  the  ligation  of  two  labeled
oligonucleotides  is  determined  by  the  allele  present.  This
technology  is  cost-effective,  robust,  accurate,  and  flexible,
but  whether  it  will  change  the  field  of  microarrays  in  the
near future remains to be seen.
David Ward (Yale University Medical School, New Haven,
USA) discussed the rolling-circle DNA amplification method
and ‘lollypop probe’ applications for the detection of point
mutations in situ. In this method, a circle of DNA, a short
DNA primer (complimentary to a portion of the circle) plus a
polymerase  (together,  a  ‘lollypop’)  generate  a  single-
stranded concatameric DNA molecule that is composed of
thousands of tandemly repeated copies of the circle. Unlike
other  amplification  techniques,  this  method  produces  a
single  amplified  product  that  remains  linked  to  the  DNA
primer, and it is thus well suited to solid-phase formats, for
example for generating localized signals at specific microar-
ray locations. Interestingly, this method has been adopted
for real-time quantitation purposes and could detect fewer
than ten molecules. Using in situ hybridization and cytome-
try,  together  with  rolling-circle  amplification,  Ward  has
determined the localization of antigens in the spirochete that
causes Lyme disease (Borrelia burgdorferi).
In  conclusion,  the  meeting  provided  an  overview  of  the
current status of gene and protein chips and their applica-
tions in diagnostics and genomics. Identification and valida-
tion  of  marker  genes  for  particular  diseases  and
determination of their clinical implications continue to be
major bottlenecks in drug discovery. 
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